Edition:
United Kingdom

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

9.60USD
18 Oct 2018
Change (% chg)

$0.02 (+0.21%)
Prev Close
$9.58
Open
$9.50
Day's High
$9.63
Day's Low
$9.39
Volume
38,821
Avg. Vol
56,131
52-wk High
$17.39
52-wk Low
$7.21

Latest Key Developments (Source: Significant Developments)

AC Immune Q2 IFRS Loss Per Share CHF 0.19
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q2 REVENUE CHF 2.0 MILLION.QTRLY IFRS LOSS PER SHARE - BASIC AND DILUTED CHF 0.19.QTRLY NON-IFRS LOSS PER SHARE - BASIC AND DILUTED CHF 0.19.  Full Article

AC Immune Announces Offerings And Issuance Of Up To 10 Mln Common Shares
Tuesday, 17 Jul 2018 

July 17 (Reuters) - AC Immune SA ::AC IMMUNE ANNOUNCES OFFERINGS AND ISSUANCE OF UP TO 10 MILLION COMMON SHARES.AC IMMUNE SA - COMMENCING OFFERINGS OF UP TO 10 MILLION NEW COMMON SHARES OF CO WITH A NOMINAL VALUE OF CHF 0.02 EACH.AC IMMUNE SA - INTENDS TO ISSUE ALL NEW COMMON SHARES AGAINST CASH CONTRIBUTIONS AS APPROVED BY COMPANY'S SHAREHOLDERS.AC IMMUNE SA - PLANS TO USE PROCEEDS FROM OFFERINGS PRIMARILY TO FUND RESEARCH & DEVELOPMENT EXPENSES FOR CO'S CLINICAL AND PRE-CLINICAL RESEARCH.  Full Article

AC Immune Reports Q1 Revenue CHF 1.5 Million
Wednesday, 2 May 2018 

May 2 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATE.Q1 REVENUE CHF 1.5 MILLION.Q1 REVENUE VIEW CHF 2 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-IFRS EPS LOSS CHF 0.19.  Full Article

AC Immune SA reports quarterly ‍loss per share CHF 0.15
Monday, 13 Nov 2017 

Nov 13 (Reuters) - AC Immune SA ::AC Immune SA reports third quarter 2017 financial results and corporate update.AC Immune SA qtrly ‍loss per share CHF 0.15 .Says qtrly adjusted loss per share CHF ‍0.16​.  Full Article

AC Immune to get milestone payment for Alzheimer drug
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - AC Immune Ltd :Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​.Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​.Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech.  Full Article

AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ac Immune Ltd :AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease.Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017.  Full Article

Essex Bio-Technology enters research project deal with AC Immune
Monday, 22 May 2017 

May 22 (Reuters) - Essex Bio-technology Ltd <1061.HK>:Company entered into research project agreement with ACI.Deal to collaborate in pre-clinical and clinical co-development of novel biological therapeutic to treat neurodegenerative diseases.  Full Article

BRIEF-AC Immune Says Co's Selling Shareholder May Sell Up To 18 Mln Common Shares

* AC IMMUNE SAYS CO'S SELLING SHAREHOLDER MAY SELL UP TO 18 MILLION COMMON SHARES Source text: (https://bit.ly/2P0dXMm) Further company coverage: